Direct Impact

Concepts for which Michael Roe Jones has direct influence:

colesevelam hcl
2 diabetes
initial combination therapy
primary hyperlipidemia
plasma glucose
insulin sensitivity
lipid profile

External impact

Concepts related to the work of other authors for which Michael Roe Jones has influence:

olmesartan medoxomil
lifestyle intervention
estrogen estradiol
colesevelam hcl
2 diabetes
endothelial dysfunction
initial combination therapy

Prominent publications by Michael Roe Jones

KOL-Index: 33 BACKGROUND AND OBJECTIVES: Colesevelam significantly lowers cholesterol in patients with hypercholesterolemia, and both cholesterol and hemoglobin A1C (A1C) in patients with type 2 diabetes mellitus (T2DM). The purpose of this post hoc analysis was to evaluate the efficacy and safety/tolerability of colesevelam in older (≥65 years) and younger (<65 years) adults. METHODS: We conducted post ...
Known for
Tolerability Colesevelam | Ldl A1c | ≥65 Younger | 16 26 Weeks
KOL-Index: 29 Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological ...
Known for
Combination Colesevelam | Statin Statins | Lipid-Lowering Therapies | Effects Lipid
KOL-Index: 18 PURPOSE: In addition to lowering hemoglobin A1C, colesevelam has been shown to improve the atherogenic lipoprotein profile of subjects with type 2 diabetes mellitus (T2DM) when used in combination with metformin and/or sulfonylureas. A recent study evaluated the effects of colesevelam as antidiabetes monotherapy in adults with T2DM who had inadequate glycemic control (hemoglobin A1C ≥7.5 to ...
Known for
Atherogenic Lipoprotein Profile | Chylomicron Particle Concentration | Colesevelam Density | Least-Squares
KOL-Index: 15 Colesevelam's glucose-lowering mechanism of action is not completely understood. Clinical trials of colesevelam suggest that its mechanism, and often adverse effects, differ from those of other oral antidiabetes drugs. Colesevelam does not affect insulin sensitivity (unlike thiazolidinediones), insulin secretion (unlike sulfonylureas and meglitinides), or early insulin response or glucagon ...
Known for
Thiazolidinediones | Mechanism Effects | Drug Action | Α-Glucosidase Inhibitors
KOL-Index: 13 BACKGROUND: Bile acid sequestrants are a well-accepted class of cholesterol-lowering drugs. Over the last decade, small studies have indicated that these agents may also lower glucose levels in patients with type 2 diabetes mellitus (T2DM). METHODS: This 26-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted between August 2004 and July 2006 at 54 sites in ...
Known for
Effects Bile | Level Baseline | Inadequately Metformin | Glycemic Lipid
KOL-Index: 12 The bile acid sequestrant, colesevelam hydrochloride, is approved for glycemic control in adults with type 2 diabetes. In three double-masked, placebo-controlled studies, colesevelam hydrochloride 3.75 g/day demonstrated its glycemic-lowering properties when added to existing metformin-, insulin-, or sulfonylurea-based therapy in adults with inadequately controlled type 2 diabetes. This was ...
Known for
Therapy Adults | Completed Extension | Masked Colesevelam | Event Mild
KOL-Index: 11
Known for
305 Response
KOL-Index: 8 OBJECTIVE: To evaluate the efficacy and safety of initial combination therapy with metformin plus colesevelam in patients with early type 2 diabetes. METHODS: In this 16-week, randomized, double-blind, placebo-controlled study, adults with type 2 diabetes (hemoglobin A1c [A1C] values of 6.5% to 10.0%) and hypercholesterolemia (low-density lipoprotein cholesterol [LDL-C] levels > or =100 ...
Known for
Colesevelam Early | High-Sensitivity C-Reactive Protein | 286 | Ldl 100
KOL-Index: 8 OBJECTIVE: This study evaluated the glycosylated hemoglobin (HbA(1c)-lowering effect of colesevelam hydrochloride, a bile acid sequestrant, in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy. METHODS: After a 4-week placebo run-in period, subjects with type 2 diabetes and an HbA(1c) value of 7.0% to 10.0% were randomized to receive ...
Known for
Treatment-Emergent | Postprandial Glucose Level | Lipid Parameters | Hba1c Baseline
KOL-Index: 8 BACKGROUND: Poor glycemic control is a risk factor for microvascular complications in patients with type 2 diabetes mellitus. Achieving glycemic control safely with insulin therapy can be challenging. METHODS: A prospective, 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted at 50 sites in the United States and 1 site in Mexico between August ...
Known for
Therapy Improving | Level Baseline | Withdrew | Colesevelam Treated

Daiichi Sankyo, Inc., Parsippany, NJ, United States

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172